ketoconazole has been researched along with Multiple Sclerosis, Relapsing-Remitting in 2 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketoconazole, known to inhibit not only CYP3A but also CYP4F2, was an inhibitor of fingolimod metabolism in HLM with an inhibition constant (K(i)) of 0." | 1.37 | CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. ( Borell, H; Jin, Y; Patten, CJ; Zimmerlin, A; Zollinger, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, Y | 1 |
| Zollinger, M | 1 |
| Borell, H | 1 |
| Zimmerlin, A | 1 |
| Patten, CJ | 1 |
| Vasiliou, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage[NCT04088630] | Early Phase 1 | 28 participants (Actual) | Interventional | 2020-08-07 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ketoconazole and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Interactions; Fingolimod Hydrochloride | 2010 |
1 other study available for ketoconazole and Multiple Sclerosis, Relapsing-Remitting
| Article | Year |
|---|---|
CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.
Topics: Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P | 2011 |